首页> Contemporary clinical trials communications> First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427).

First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427).

导出 LinkOut

翻译打印收藏纠错

第一作者： Toan,Pham

第一单位： Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia.;Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.;Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.;Department of Surgery, University of Melbourne, Melbourne, Australia.

作者： Toan,Pham ^[1] ; Lloyd,Pereira ^[2] ; Sara,Roth ^[2] ; Laura,Galletta ^[2] ; Emma,Link ^[2] ; Tim,Akhurst ^[3] ; Ben,Solomon ^[4] ; Michael,Michael ^[4] ; Phillip,Darcy ^[2] ; Shienny,Sampurno ^[2] ; Alexander,Heriot ^[1] ; Robert,Ramsay ^[5] ; Jayesh,Desai ^[4]

作者单位： Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia.;Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.;Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.;Department of Surgery, University of Melbourne, Melbourne, Australia. ^[1] Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia. ^[2] Division of Medical Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia. ^[3] Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.;Division of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. ^[4] Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia.;Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.;Department of Pathology, University of Melbourne, Melbourne, Australia. ^[5]

关键词 Adenoid cystic carcinoma Cancer vaccine Colorectal neoplasms Glandular and epithelial neoplasms Immune checkpoint therapy Immunotherapy

DOI 10.1016/j.conctc.2019.100409

PMID 31650066

发布时间 2022-04-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览4

Contemporary clinical trials communications

2019年16卷

100409页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览4

点击下载本期目录封面

Contemporary clinical trials communications

2019年16卷

100409页

检索历史清除

First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427).

Contemporary clinical trials communications

相似文献

同项目论文

Contemporary clinical trials communications

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427).

Contemporary clinical trials communications

相似文献

同项目论文

Contemporary clinical trials communications

相关期刊

检索历史清除